N/A
Completed N=156
Hereditary Haemorrhagic Telangiectasia Flight Safety Study
Hereditary Haemorrhagic Telangiectasia
Source: ClinicalTrials.gov NCT01590121 ↗
Enrolled (actual)
156
Serious AEs
0.0%
Results posted
Nov 2024
Primary outcomePrimary: HHT Patients Who by the Questionnaire Did or Did Not Self Report a Medical Complication During Flight — 77 percentage of patients
Summary
Hereditary Haemorrhagic Telangiectasia (HHT) is a condition in which sufferers have abnormal blood vessels which makes them more likely to bleed than other people, particularly in the lungs, which results in low blood oxygen levels. Flying may make this worse and cause problems. The investigators want to know if there are an increased number of problems on flights compared to on land.
The investigators currently do not have any evidence based guidelines on air travel to best advice people who suffer with HHT. The investigators would therefore like to ask individuals who have HHT about their experience on a flight, using a postal questionnaire.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY HHT Patients Who by the Questionnaire Did or Did Not Self Report a Medical Complication During Flight |
77 | — |
Eligibility Criteria
Inclusion Criteria
HHT
Exclusion Criteria
Unable to provide informed consent
Data sourced from ClinicalTrials.gov (NCT01590121). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.